TP53 and B-cell chronic lymphocytic leukemia: In the multicenter iLLUMINATE phase 3 study, ibrutinib plus obinutuzumab therapy showed significantly prolonged PFS than the standard chlorambucil plus obinutuzumab treatment (30-month PFS: 79% vs. 31%) in previously untreated CLL patients, including high-risk patients with del(17p), del(11q), TP53 mutation and unmutated IGHV [150].